海外の治験の状況「前立腺癌」での検索結果
118件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not Recruiting
- A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Australia, Chile, France, Germany, Italy, Mexico, Netherlands, Spain, United Kingdom, United States
- 2015-10-23
Not recruiting
- A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, United Kingdom, United States
- 2013-10-31
Not Recruiting
- RANDOMIZED, OPEN LABEL, MULTI-CENTER STUDY COMPARING CABAZITAXEL AT 25 MG/M2 AND AT 20 MG/M² IN COMBINATION WITH PREDNISONE EVERY 3 WEEKS TO DOCETAXEL IN COMBINATION WITH PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER NOT PRETREATED WITH CHEMOTHERAPY
- Australia, Belarus, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Japan, Mexico, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United States
- 2011-05-12
Not Recruiting
- Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
- castration-resistant metastatic prostate cancer. br>MedDRA version: 14.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Brazil, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Korea, Republic of, Mexico, Norway, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, United Kingdom, United States
- 2008-09-05
Not Recruiting
- A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
- Metastatic Castration- Resistant Prostate Cancer (mCRPC);C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Canada, Chile, Czech Republic, Finland, France, Germany, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Spain, Sweden, Taiwan, Province of China, United Kingdom, United States
- 2014-10-01
Not recruiting
- Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina
- Advanced Hormone Dependent Prostate Cancer
- Argentina
- 2013-05-21
Not Recruiting
- A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)
- Prostate Cancer # Metastatic # Hormone Refractory;C61 - Malignant neoplasm of prostate
- Brazil, Germany, Hungary, South Africa, Sweden
- 2012-10-18
Not Recruiting
- Preoperative physiotherapy for radical prostatectomy
- Prostate cancer, urinary incontinence, impotence of organic origin C61 N39.4 N48.4;C00-D48
- Brazil
- 2017-06-27
Not Recruiting
- A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen
- Prostate Cancer # Hormone Refractory Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Belgium, Croatia, France, Germany, Hungary, Israel, Italy, Netherlands, Peru, Poland, Russian Federation, Spain, United Kingdom, United States
- 2015-11-12
Not Recruiting
- Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer
- Metastatic castrate-resistant prostate cancer br>MedDRA version: 14.0 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Costa Rica, Czech Republic, Denmark, Estonia, European Union, Finland, Germany, Greece, Hungary, India, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Panama, Peru, Russian Federation, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2006-03-31
